Status:
UNKNOWN
A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)
Lead Sponsor:
West China Hospital
Conditions:
Prostate Cancer Metastatic
Eligibility:
MALE
40+ years
Brief Summary
The investigators plan to perform multi-omics technologies, including genomic, transcriptomic, epigenomic and proteomic methods, in patients with metastatic prostate cancer, aiming at uncovering the m...
Detailed Description
Prostate cancer is the commonest malignancy and the second leading cause of tumor-related death among males worldwide. Though patients with early stage prostate cancer can obtain satisfactory therapeu...
Eligibility Criteria
Inclusion
- Pathological confirmation of prostate cancer
- Age: ≥40 years old
- Bone or visceral metastatic disease confirmed by image examination.
- Written informed consent
Exclusion
- Patients harbouring other types of cancer besides prostate cancer
Key Trial Info
Start Date :
August 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04660617
Start Date
August 1 2021
End Date
April 1 2023
Last Update
May 11 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.